| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/02/2005 | US20050119465 Glycosylated follicle stimulating hormone for use as therapeutic tool in treatment of reproductive disorders |
| 06/02/2005 | US20050119450 Biodegradable polyphosphoramidates for controlled release of bioactive substances |
| 06/02/2005 | US20050119385 Process for production of pressure-sensitive adhesive moldings comprising crosslinked polymers as the main component |
| 06/02/2005 | US20050119340 Reversed cubic phase or reversed hexagonal phase liquid crystal; provide sustained action and/or reduced dosage requirements; bupivacaine |
| 06/02/2005 | US20050119313 Aqueous antiseptic based on bispyridiniumalkanes |
| 06/02/2005 | US20050119299 Ophthalmic solutions containing tetrazole derivatives |
| 06/02/2005 | US20050119281 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom |
| 06/02/2005 | US20050119223 Injectable solution containing a shark-derived chondroitin sulfate iron colloid |
| 06/02/2005 | US20050119219 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring |
| 06/02/2005 | US20050119212 Controlling gene expression; spinal cord injuries |
| 06/02/2005 | US20050119211 Moderators of gene expression; mixture of small nucleic acids |
| 06/02/2005 | US20050119193 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same |
| 06/02/2005 | US20050119172 Purity, genetic engineered human serum albumin for Factor viii |
| 06/02/2005 | US20050119170 Therapy for anaphylactic shock |
| 06/02/2005 | US20050119166 Complex of cytotoxic agent with aoligopeptide; amino acid sequence proteolytic splitting prostate specific antigen; prostate cancer; benign prostatic hyperplasia |
| 06/02/2005 | US20050118718 Stabilization and controlled delivery of ionic biopharmaceuticals |
| 06/02/2005 | US20050118281 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent. |
| 06/02/2005 | US20050118272 Micronized pharmaceutical or nutraceutical powder with immediate release |
| 06/02/2005 | US20050118271 Polytartrate composition |
| 06/02/2005 | US20050118270 Method of formation of shape-retentive aggregates of gel particles and their uses |
| 06/02/2005 | US20050118268 Timed pulsatile drug delivery systems |
| 06/02/2005 | US20050118261 Compositions and methods of administering doxepin to mucosal tissue |
| 06/02/2005 | US20050118258 Pharmaceutical composition comprising skim milk powder |
| 06/02/2005 | US20050118254 hydrophilic solvent, an oil, and a surfactant, and a pharmaceutically active component; hydrophilic solvent selected from the group consisting of propylene glycol diacetate, propylene glycol monoacetate, and salts |
| 06/02/2005 | US20050118253 comprising a nucleic acid that is fully encapsulated within a lipid; for treating a neoplasia in a mammal |
| 06/02/2005 | US20050118248 fatty acid chain are derived from natural vegetable oils such as vernonia oil, lesquerella oil and castor oil, in which the several reactive groups such as epoxy, hydroxy and double bonds can be modified to polar and ionic groups |
| 06/02/2005 | US20050118244 penetration promoter; hormone replacement therapy; contraception |
| 06/02/2005 | US20050118242 Using testosterone; topical applying to skins |
| 06/02/2005 | US20050118241 emulsion comprises a mixture of lecithin(s), bile salts and cholesterol in water; advantage of the non-oily emulsion is the remarkably quick absorption of an active ingredient into the circulation |
| 06/02/2005 | US20050118231 Water-soluble excipient biocompatible with an ophthalmic use: carbohydrates, gums, sodium salts, calcium salts, magnesium salts, maltodextrins, cellulose derivatives, chitosans, destructured/ partially hydrolyzed/crosslinked starches, polyvinyl alcohol, polyacrylic acid; disintegrate and release drug |
| 06/02/2005 | US20050118221 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
| 06/02/2005 | US20050118217 Rapidly disintegrating films for delivery of pharmaceutical of cosmetic agents |
| 06/02/2005 | US20050118211 Water-in-oil emulsion composition and emulsion cosmetic comprising the same |
| 06/02/2005 | US20050118206 A surfactant, a solvent, and a beneficial agent; exposure to a hydrophilic environment, surfactant and solvent form a viscous gel and beneficial agent dispersed or dissolved in the gel; |
| 06/02/2005 | US20050118205 Artificial sweetener, a sugar sweetener and a flavoring agent to mask a bitter antibiotic such as levofloxacin |
| 06/02/2005 | US20050118199 Process for covalently conjugating polysaccharides to microspheres or biomolecules |
| 06/02/2005 | US20050118194 Oral vaccine, method for its preparation and use thereof |
| 06/02/2005 | US20050118190 Staphylococcus antigen and vaccine |
| 06/02/2005 | US20050118182 Conjugated to radioisotope, drug, cyotoxic agent or biodrug; immunotoxin of use to treat cancer; immunoassay kit for detection of CD 22+ cancer cells |
| 06/02/2005 | US20050118178 Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy |
| 06/02/2005 | US20050118167 Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof |
| 06/02/2005 | US20050118165 useful for imaging such tumors; scintigraphic detection, diagnosis, prognosis, monitoring and therapy of Met-bearing tumors |
| 06/02/2005 | US20050118163 Antibody-containing solution pharmaceuticals |
| 06/02/2005 | US20050118136 Polyaspartic acid or polyglutamic acid end capped by oligopeptides of various amino acid sequences; improved pharmacokinetics, bioavailability and water solubility of conjugated drugs |
| 06/02/2005 | US20050118113 Powder particles with smooth surface for use in inhalation therapy |
| 06/02/2005 | US20050118107 Formoterol combined with polyvinylpyrrolidone, polyethylene glycol, HFA 227 and HFA 134a; stable in pressurized meter dosage interior coated cans fitted with retention valve |
| 06/02/2005 | US20050118102 Superparamagnetic nanoparticles with attached, specific targeting moiety; providing in vivo heating |
| 06/02/2005 | US20050118101 Delivery across skin or blood brain barrier; such as N-(fluorescein-5-yl)-thioureido-N'-Adoa-(polylysine)7-NH2 TFA salt |
| 06/02/2005 | US20050118099 Thiol-mediated drug attachment to targeting peptides |
| 06/02/2005 | DE10350654A1 Composition used as or for producing pharmaceutical product for topical application or implantation in humans or animals to promote healing, has collagen-containing substrate containing polymer particles containing active substance |
| 06/02/2005 | CA2747871A1 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 06/02/2005 | CA2546396A1 Method and composition for treatment of cutaneous lesions |
| 06/02/2005 | CA2546383A1 Rescue agents for treating botulinum toxin intoxications |
| 06/02/2005 | CA2546237A1 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| 06/02/2005 | CA2546227A1 Methods of preparing a foam comprising a sclerosing agent |
| 06/02/2005 | CA2546195A1 The use of anti biotics as vaccine adjuvants |
| 06/02/2005 | CA2546108A1 Methods of preparing a foam comprising a sclerosing agent |
| 06/02/2005 | CA2546076A1 Therapeutic foam |
| 06/02/2005 | CA2545939A1 Immunoglobulin preparations having increased stability |
| 06/02/2005 | CA2545923A1 Excipients in drug delivery vehicles |
| 06/02/2005 | CA2545919A1 Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer |
| 06/02/2005 | CA2545915A1 Minimization of drug oxidation in drug irradiated excipients formulations |
| 06/02/2005 | CA2545913A1 An injectable depot gel composition, a method of preparation and use thereof |
| 06/02/2005 | CA2545856A1 Compositions comprising antibodies and methods of using the same for targeted nanoparticulate active agent delivery |
| 06/02/2005 | CA2545855A1 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 06/02/2005 | CA2545800A1 Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| 06/02/2005 | CA2545267A1 Inhibitor imaging agents |
| 06/02/2005 | CA2545034A1 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| 06/02/2005 | CA2533884A1 Preventative effects of morinda citrifolia on mammary breast cancer |
| 06/01/2005 | EP1535993A1 Biomolecule transfer method using virus envelope and composition and system therefor |
| 06/01/2005 | EP1535916A1 Clathrates of butylphtualide with cyclodextrin or its derivatives,a process for their preparations and the use there of |
| 06/01/2005 | EP1535903A1 Modified MscL protein channel |
| 06/01/2005 | EP1535623A1 Renal cell carcinoma treatment |
| 06/01/2005 | EP1535622A1 Melanoma therapy |
| 06/01/2005 | EP1535615A1 Composition for nasal absorption |
| 06/01/2005 | EP1534837A2 Apicomplexan pathways, inhibitiors, and drug delivery |
| 06/01/2005 | EP1534823A2 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 06/01/2005 | EP1534753A2 Antibody peg positional isomers, compositions comprising same, and use thereof |
| 06/01/2005 | EP1534750A2 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 06/01/2005 | EP1534746A2 Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins |
| 06/01/2005 | EP1534741A1 Fiber-shaping peptides capable of interacting with self-assembling peptides |
| 06/01/2005 | EP1534730A2 Modified transferin-antibody fusion proteins |
| 06/01/2005 | EP1534720A1 Mitochondrially targeted antioxidants |
| 06/01/2005 | EP1534682A1 Novel molecules derived from noraporphine |
| 06/01/2005 | EP1534670A1 Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs |
| 06/01/2005 | EP1534512A1 Coated particles, methods of making and using |
| 06/01/2005 | EP1534347A2 Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds |
| 06/01/2005 | EP1534343A1 Non-glycosylated polyacrylamide conjugates and their use for cytoprotection |
| 06/01/2005 | EP1534342A1 Modified saccharides, conjugates thereof, and their manufacture |
| 06/01/2005 | EP1534341A1 Therapeutic system targeting pathogen proteases and uses thereof |
| 06/01/2005 | EP1534340A2 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
| 06/01/2005 | EP1534339A1 Topical anhydrous and ethanol-free ascomycin compositions |
| 06/01/2005 | EP1534334A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 06/01/2005 | EP1534324A2 Tumor specific oligosaccharide epitopes and use thereof |
| 06/01/2005 | EP1534322A1 Minibrain homologous proteins involved in the regulation of energy homeostasis |
| 06/01/2005 | EP1534317A2 N-terminally truncated galectin-3 and antibodies for treating cancer |
| 06/01/2005 | EP1534315A2 Increasing of the resorption of substances via skin and mucous membranes |
| 06/01/2005 | EP1534308A2 Peptides with growth inhibitory action |
| 06/01/2005 | EP1534297A1 Methods of treatment of male erectile dysfunction |
| 06/01/2005 | EP1534288A1 Stable aqueous solutions of risperidone and methods for their preparation |